EMD Millipore has been contracted to supply raw materials to the Samsung Biologics plant where ingredients for BM-S’ anticancer monoclonal antibody Yervoy (ipilimumab) are made.
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.